Medical Care

Global Peptide Based Infection Therapeutics Market Research Report 2024

Peptide therapeutics are stable, safe, tolerable, possess selective nature, and effective.
The global Peptide Based Infection Therapeutics market was valued at US$ 23470 million in 2023 and is anticipated to reach US$ 34800 million by 2030, witnessing a CAGR of 5.3% during the forecast period 2024-2030.
Hospital pharmacies segment enjoys the highest market share by revenue thereby dominating the global market.
This report aims to provide a comprehensive presentation of the global market for Peptide Based Infection Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Based Infection Therapeutics.
Report Scope
The Peptide Based Infection Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Based Infection Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide Based Infection Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Johnson & Johnson (Janssen)
Vertex Pharmaceuticals
Mitsubishi Tanabe Pharma
Medivir
Segment by Type
Telaprevir
Sofosbuvir
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Based Infection Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide Based Infection Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Telaprevir
1.2.3 Sofosbuvir
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peptide Based Infection Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide Based Infection Therapeutics Market Perspective (2019-2030)
2.2 Peptide Based Infection Therapeutics Growth Trends by Region
2.2.1 Global Peptide Based Infection Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Peptide Based Infection Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Peptide Based Infection Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Peptide Based Infection Therapeutics Market Dynamics
2.3.1 Peptide Based Infection Therapeutics Industry Trends
2.3.2 Peptide Based Infection Therapeutics Market Drivers
2.3.3 Peptide Based Infection Therapeutics Market Challenges
2.3.4 Peptide Based Infection Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide Based Infection Therapeutics Players by Revenue
3.1.1 Global Top Peptide Based Infection Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Peptide Based Infection Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Peptide Based Infection Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide Based Infection Therapeutics Revenue
3.4 Global Peptide Based Infection Therapeutics Market Concentration Ratio
3.4.1 Global Peptide Based Infection Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide Based Infection Therapeutics Revenue in 2023
3.5 Peptide Based Infection Therapeutics Key Players Head office and Area Served
3.6 Key Players Peptide Based Infection Therapeutics Product Solution and Service
3.7 Date of Enter into Peptide Based Infection Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide Based Infection Therapeutics Breakdown Data by Type
4.1 Global Peptide Based Infection Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Peptide Based Infection Therapeutics Forecasted Market Size by Type (2025-2030)
5 Peptide Based Infection Therapeutics Breakdown Data by Application
5.1 Global Peptide Based Infection Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Peptide Based Infection Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Peptide Based Infection Therapeutics Market Size (2019-2030)
6.2 North America Peptide Based Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Peptide Based Infection Therapeutics Market Size by Country (2019-2024)
6.4 North America Peptide Based Infection Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide Based Infection Therapeutics Market Size (2019-2030)
7.2 Europe Peptide Based Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Peptide Based Infection Therapeutics Market Size by Country (2019-2024)
7.4 Europe Peptide Based Infection Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide Based Infection Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Peptide Based Infection Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide Based Infection Therapeutics Market Size (2019-2030)
9.2 Latin America Peptide Based Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Peptide Based Infection Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Peptide Based Infection Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide Based Infection Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Peptide Based Infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Detail
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Peptide Based Infection Therapeutics Introduction
11.1.4 Gilead Sciences Revenue in Peptide Based Infection Therapeutics Business (2019-2024)
11.1.5 Gilead Sciences Recent Development
11.2 Johnson & Johnson (Janssen)
11.2.1 Johnson & Johnson (Janssen) Company Detail
11.2.2 Johnson & Johnson (Janssen) Business Overview
11.2.3 Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Introduction
11.2.4 Johnson & Johnson (Janssen) Revenue in Peptide Based Infection Therapeutics Business (2019-2024)
11.2.5 Johnson & Johnson (Janssen) Recent Development
11.3 Vertex Pharmaceuticals
11.3.1 Vertex Pharmaceuticals Company Detail
11.3.2 Vertex Pharmaceuticals Business Overview
11.3.3 Vertex Pharmaceuticals Peptide Based Infection Therapeutics Introduction
11.3.4 Vertex Pharmaceuticals Revenue in Peptide Based Infection Therapeutics Business (2019-2024)
11.3.5 Vertex Pharmaceuticals Recent Development
11.4 Mitsubishi Tanabe Pharma
11.4.1 Mitsubishi Tanabe Pharma Company Detail
11.4.2 Mitsubishi Tanabe Pharma Business Overview
11.4.3 Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Introduction
11.4.4 Mitsubishi Tanabe Pharma Revenue in Peptide Based Infection Therapeutics Business (2019-2024)
11.4.5 Mitsubishi Tanabe Pharma Recent Development
11.5 Medivir
11.5.1 Medivir Company Detail
11.5.2 Medivir Business Overview
11.5.3 Medivir Peptide Based Infection Therapeutics Introduction
11.5.4 Medivir Revenue in Peptide Based Infection Therapeutics Business (2019-2024)
11.5.5 Medivir Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Peptide Based Infection Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Telaprevir
Table 3. Key Players of Sofosbuvir
Table 4. Key Players of Others
Table 5. Global Peptide Based Infection Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Peptide Based Infection Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Peptide Based Infection Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Peptide Based Infection Therapeutics Market Share by Region (2019-2024)
Table 9. Global Peptide Based Infection Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Peptide Based Infection Therapeutics Market Share by Region (2025-2030)
Table 11. Peptide Based Infection Therapeutics Market Trends
Table 12. Peptide Based Infection Therapeutics Market Drivers
Table 13. Peptide Based Infection Therapeutics Market Challenges
Table 14. Peptide Based Infection Therapeutics Market Restraints
Table 15. Global Peptide Based Infection Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Peptide Based Infection Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Peptide Based Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Based Infection Therapeutics as of 2023)
Table 18. Ranking of Global Top Peptide Based Infection Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Peptide Based Infection Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peptide Based Infection Therapeutics Product Solution and Service
Table 22. Date of Enter into Peptide Based Infection Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peptide Based Infection Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Peptide Based Infection Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Peptide Based Infection Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Peptide Based Infection Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Peptide Based Infection Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Peptide Based Infection Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Peptide Based Infection Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Peptide Based Infection Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Peptide Based Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Peptide Based Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Peptide Based Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Peptide Based Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Peptide Based Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Peptide Based Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Peptide Based Infection Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Peptide Based Infection Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Peptide Based Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Peptide Based Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Peptide Based Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Peptide Based Infection Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Peptide Based Infection Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Gilead Sciences Company Detail
Table 48. Gilead Sciences Business Overview
Table 49. Gilead Sciences Peptide Based Infection Therapeutics Product
Table 50. Gilead Sciences Revenue in Peptide Based Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Gilead Sciences Recent Development
Table 52. Johnson & Johnson (Janssen) Company Detail
Table 53. Johnson & Johnson (Janssen) Business Overview
Table 54. Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Product
Table 55. Johnson & Johnson (Janssen) Revenue in Peptide Based Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Johnson & Johnson (Janssen) Recent Development
Table 57. Vertex Pharmaceuticals Company Detail
Table 58. Vertex Pharmaceuticals Business Overview
Table 59. Vertex Pharmaceuticals Peptide Based Infection Therapeutics Product
Table 60. Vertex Pharmaceuticals Revenue in Peptide Based Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Vertex Pharmaceuticals Recent Development
Table 62. Mitsubishi Tanabe Pharma Company Detail
Table 63. Mitsubishi Tanabe Pharma Business Overview
Table 64. Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Product
Table 65. Mitsubishi Tanabe Pharma Revenue in Peptide Based Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Mitsubishi Tanabe Pharma Recent Development
Table 67. Medivir Company Detail
Table 68. Medivir Business Overview
Table 69. Medivir Peptide Based Infection Therapeutics Product
Table 70. Medivir Revenue in Peptide Based Infection Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Medivir Recent Development
Table 72. Research Programs/Design for This Report
Table 73. Key Data Information from Secondary Sources
Table 74. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Based Infection Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Peptide Based Infection Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Telaprevir Features
Figure 4. Sofosbuvir Features
Figure 5. Others Features
Figure 6. Global Peptide Based Infection Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Peptide Based Infection Therapeutics Market Share by Application: 2023 VS 2030
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Peptide Based Infection Therapeutics Report Years Considered
Figure 12. Global Peptide Based Infection Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Peptide Based Infection Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Peptide Based Infection Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Peptide Based Infection Therapeutics Market Share by Players in 2023
Figure 16. Global Top Peptide Based Infection Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Based Infection Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Peptide Based Infection Therapeutics Revenue in 2023
Figure 18. North America Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Peptide Based Infection Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Peptide Based Infection Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Peptide Based Infection Therapeutics Market Share by Region (2019-2030)
Figure 32. China Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Peptide Based Infection Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Peptide Based Infection Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Peptide Based Infection Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Gilead Sciences Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2019-2024)
Figure 47. Johnson & Johnson (Janssen) Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2019-2024)
Figure 48. Vertex Pharmaceuticals Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2019-2024)
Figure 49. Mitsubishi Tanabe Pharma Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2019-2024)
Figure 50. Medivir Revenue Growth Rate in Peptide Based Infection Therapeutics Business (2019-2024)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies